[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100501085":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":27,"responsibleParty":49,"collaborators":20,"id":51,"slug":20,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":20,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":20,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":30,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Crinetics Pharmaceuticals Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multiple Ascending Doses","EXPERIMENTAL","Sequential, open-label, 10-day or 14-day fixed-dose cohorts.",[13],"Drug: atumelnant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","atumelnant","Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Crinetics Clinical Trials","CONTACT","833-827-9741","clinicaltrials@crinetics.com",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","RECRUITING","Bethesda","Maryland","20892","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-77.10026,38.98067,{"lat":40,"lon":39},[43,47],{"name":44,"role":24,"phone":45,"phoneExt":20,"email":46},"Lynnette K Nieman, MD","301-496-8935","niemanl@nih.gov",{"name":44,"role":48,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100501085",false,"NCT05804669","A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","A Phase 1b\u002F2a Open-label Multiple-ascending Dose Exploratory Study of CRN04894 in ACTH-dependent Cushing's Syndrome (Cushing's Disease or Ectopic ACTH Syndrome)","Inclusion Criteria:\n\n1. Adult male or female, aged 18 years or more\n2. Evidence of chronic 'active' ACTH-dependent Cushing's syndrome\n3. Evidence of acutely 'active' ACTH-dependent Cushing's syndrome within 10 days of Day 1\n4. Participants with documented ACTH-dependent Cushing's syndrome taking short-acting steroidogenesis inhibitors (ketoconazole, levoketoconazole, osilodrostat, or metyrapone) may participate after a washout period of at least 5 days, if they meet other study inclusion criteria, relative to Investigator's judgment. Participants with documented ACTH-dependent Cushing's syndrome taking cabergoline may participate after a washout period of at least 14 days, if they meet other study inclusion criteria\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating\n2. History of bilateral adrenalectomy\n3. Previous pituitary MRI findings of a putative ACTH-secreting lesion within 3 mm of the optic chiasm\n4. Presence of any known malignancy\n5. Use of mitotane\n6. Previous unsuccessful surgery for Cushing's syndrome within 6 weeks","ALL","18 Years",{"count":60,"type":61},18,"ESTIMATED","INTERVENTIONAL",[64,65],"PHASE1","PHASE2","A Phase 1b\u002F2a, first-in-disease, open-label, multiple-ascending dose exploratory study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamic biomarker responses associated with CRN04894 (an adrenocorticotropic hormone \\[ACTH\\] receptor antagonist) in participants with ACTH-dependent Cushing's syndrome (Cushing's disease or Ectopic ACTH Syndrome \\[EAS\\])",[68,69,70],"Cushing Syndrome","Cushing Disease","Ectopic ACTH Syndrome",[68,69,70,72,17],"CRN04894","2026-06-02",{"date":75,"type":76},"2026-06-04","ACTUAL",{"date":78,"type":76},"2023-10-12",{"date":80,"type":61},"2026-10",{"name":5,"class":6},1]